Twist Bioscience Corporation (NASDAQ:TWST) Accelerates Delivery And Strengthens Short-Term Momentum

Operational moves and corporate filings point to tighter execution and near-term technical upside; fundamental cash buffers and margin pressures frame a cautious recovery case.

Recent News

On July 7, 2025 the company shortened Express turnaround times for all gene fragments, offering two-business-day shipping and standardized pricing. On July 24, 2025 Twist announced inducement equity grants totaling 70,254 awards to recently hired personnel. Early August filings show several executives sold shares on August 4, 2025. Mid-August 2025 reporting indicated Invesco reduced its position by 200,205 shares. In early September 2025 the CEO scheduled presentations at the Baird 2025 Global Healthcare Conference and Morgan Stanley investor meetings.

Technical Analysis

Directional indicators show a lack of a clear trend: ADX at 16.9 signals no trend, while DI+ peaked-and-reversed and DI- dipped-and-reversed, producing a bearish directional bias that weakens conviction for sustained trend continuation.

MACD sits at -$0.38 and trades above its signal line at -$0.66, with an increasing MACD trend; that cross indicates improving bullish momentum from a negative baseline and supports a near-term bounce narrative.

MRO registers -16.28, indicating price sits below the model target and may move higher toward that target; the magnitude implies a measurable—but not extreme—mean-reversion potential if momentum confirms.

RSI at 44.5 and rising reflects building conviction without overbought pressure; momentum remains constructive only if RSI breaches mid-range levels on follow-through volume.

Price sits at $27.00, above the 20-day average ($26.70) but below the 50-day ($28.55) and 200-day ($37.36), which places the stock in a short-term recovery inside a longer-term downtrend. The 12-day EMA shows a peak-and-reversal pattern, adding short-term bearish friction until investors push price back above the 50-day average.

Bollinger bands place the 1x upper band at $27.95 with current price inside the upper band, suggesting limited immediate upside without a volatility expansion. Ichimoku components (Senkou A $30.52, Senkou B $31.82) keep price beneath the cloud, implying overhead resistance until price reclaims the cloud. The super trend upper at $28.13 sits as a near-term resistance level to watch.

 


Fundamental Analysis

Profitability shows operating pressure: operating income and EBIT both sit at -$30,120,000 and operating margin equals -31.356%. Operating margin declined QoQ by -25.41% and YoY by -70.08%. The operating margin sits below the industry peer mean of 19.345% and below the industry peer median of 19.467%, while remaining above the industry peer low of -167.282%.

Net income records a positive $20,390,000 despite negative operating income, supported by income before tax of $20,581,000 and interest income of $2,690,000. EPS actual measured at $-0.47 beat the estimate of $-0.57 by $0.10, a positive EPS surprise of 17.54%.

Top-line and growth metrics diverge: reported total revenue equals $96,057,000. Revenue growth figures show a trailing value of 3.518%, while quarter-over-quarter revenue contracted by -23.505% and year-over-year revenue declined by -57.008%.

Liquidity and balance sheet strength provide runway: cash and short-term investments total $250,798,000, cash ratio 2.88, current ratio 3.90 and quick ratio 3.60, signaling strong near-term coverage of liabilities. Free cash flow sits at -$10,565,000 and free cash flow yield at -0.56%, with free cash growth down -38.33% YoY, indicating operating cash generation requires improvement to match liquidity levels long-term.

Capital structure remains conservative: total debt $78,150,000, debt-to-equity 0.163, and debt-to-assets 0.121. Return metrics show return on equity 4.264% and return on assets 3.291%, modest positives given the operating loss profile. Gross margin at 53.403% improved YoY and QoQ, supporting product-level economics despite operating leverage pressure from fixed costs and R&D ($18,047,000).

Valuation context: P/B equals 3.98, marginally below the industry peer mean of 4.04 and above the industry peer median of 3.43. PS ratio at 19.80 sits above the industry peer mean of 17.18. EVR reads 18.00 and enterprise value totals $1,729,352,251. WMDST values the stock as under-valued based on the firm’s cash position, revenue profile, and growth-adjusted multiples.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-06-30
REPORT DATE: 2025-08-04
NEXT REPORT DATE: 2025-10-30
CASH FLOW  Begin Period Cash Flow 212.9 M
 Operating Cash Flow -1.40 M
 Capital Expenditures -9.16 M
 Change In Working Capital 3.8 M
 Dividends Paid
 Cash Flow Delta -9.04 M
 End Period Cash Flow 203.9 M
 
INCOME STATEMENT REVENUE
 Total Revenue 96.1 M
 Forward Revenue -43.05 M
COSTS
 Cost Of Revenue 44.8 M
 Depreciation 6.1 M
 Depreciation and Amortization 6.1 M
 Research and Development 18.0 M
 Total Operating Expenses 126.2 M
PROFITABILITY
 Gross Profit 51.3 M
 EBITDA -24.05 M
 EBIT -30.12 M
 Operating Income -30.12 M
 Interest Income 2.7 M
 Interest Expense
 Net Interest Income 2.7 M
 Income Before Tax 20.6 M
 Tax Provision 191.0 K
 Tax Rate 0.928 %
 Net Income 20.4 M
 Net Income From Continuing Operations 20.4 M
EARNINGS
 EPS Estimate -0.57
 EPS Actual -0.47
 EPS Difference 0.10
 EPS Surprise 17.544 %
 Forward EPS -0.61
 
BALANCE SHEET ASSETS
 Total Assets 643.6 M
 Intangible Assets 95.9 M
 Net Tangible Assets 382.3 M
 Total Current Assets 339.8 M
 Cash and Short-Term Investments 250.8 M
 Cash 201.4 M
 Net Receivables 49.9 M
 Inventory 25.9 M
 Long-Term Investments 6.4 M
LIABILITIES
 Accounts Payable 12.0 M
 Short-Term Debt
 Total Current Liabilities 87.1 M
 Net Debt
 Total Debt 78.2 M
 Total Liabilities 165.4 M
EQUITY
 Total Equity 478.2 M
 Retained Earnings -1.29 B
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 7.95
 Shares Outstanding 60.174 M
 Revenue Per-Share 1.60
VALUATION
 Market Capitalization 1.9 B
 Enterprise Value 1.7 B
 Enterprise Multiple -71.892
Enterprise Multiple QoQ 3.127 %
Enterprise Multiple YoY 112.813 %
Enterprise Multiple IPRWA high: 142.585
mean: 72.584
median: 72.241
TWST: -71.892
low: -148.838
 EV/R 18.003
CAPITAL STRUCTURE
 Asset To Equity 1.346
 Asset To Liability 3.891
 Debt To Capital 0.14
 Debt To Assets 0.121
Debt To Assets QoQ -9.932 %
Debt To Assets YoY 166.177 %
Debt To Assets IPRWA high: 0.847
median: 0.348
mean: 0.327
TWST: 0.121
low: 0.051
 Debt To Equity 0.163
Debt To Equity QoQ -10.425 %
Debt To Equity YoY 175.738 %
Debt To Equity IPRWA high: 3.117
median: 0.697
mean: 0.676
TWST: 0.163
low: 0.067
PRICE-BASED VALUATION
 Price To Book (P/B) 3.977
Price To Book QoQ -28.548 %
Price To Book YoY -31.796 %
Price To Book IPRWA high: 8.583
mean: 4.041
TWST: 3.977
median: 3.432
low: 0.246
 Price To Earnings (P/E) -75.925
Price To Earnings QoQ 22.433 %
Price To Earnings YoY 128.035 %
Price To Earnings IPRWA high: 111.763
mean: 81.604
median: 79.394
low: -74.764
TWST: -75.925
 PE/G Ratio 2.637
 Price To Sales (P/S) 19.801
Price To Sales QoQ -25.002 %
Price To Sales YoY -43.682 %
Price To Sales IPRWA high: 37.916
TWST: 19.801
mean: 17.178
median: 15.972
low: 0.528
FORWARD MULTIPLES
Forward P/E -58.114
Forward PE/G 2.019
Forward P/S -44.178
EFFICIENCY OPERATIONAL
 Operating Leverage -6.479
ASSET & SALES
 Asset Turnover Ratio 0.155
Asset Turnover Ratio QoQ 0.59 %
Asset Turnover Ratio YoY 27.597 %
Asset Turnover Ratio IPRWA high: 0.184
TWST: 0.155
mean: 0.118
median: 0.108
low: 0.038
 Receivables Turnover 1.925
Receivables Turnover Ratio QoQ -7.414 %
Receivables Turnover Ratio YoY -19.683 %
Receivables Turnover Ratio IPRWA high: 2.963
TWST: 1.925
mean: 1.342
median: 1.273
low: 0.962
 Inventory Turnover 1.913
Inventory Turnover Ratio QoQ -9.237 %
Inventory Turnover Ratio YoY 21.873 %
Inventory Turnover Ratio IPRWA TWST: 1.913
high: 1.196
median: 1.196
mean: 0.988
low: 0.187
 Days Sales Outstanding (DSO) 47.404
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 73.502
Cash Conversion Cycle Days QoQ 1.318 %
Cash Conversion Cycle Days YoY -12.302 %
Cash Conversion Cycle Days IPRWA high: 448.101
mean: 132.842
median: 107.055
TWST: 73.502
low: 51.486
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.38
 CapEx To Revenue -0.095
 CapEx To Depreciation -1.511
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 478.2 M
 Net Invested Capital 478.2 M
 Invested Capital 478.2 M
 Net Tangible Assets 382.3 M
 Net Working Capital 252.7 M
LIQUIDITY
 Cash Ratio 2.88
 Current Ratio 3.902
Current Ratio QoQ -13.551 %
Current Ratio YoY -20.453 %
Current Ratio IPRWA high: 12.395
TWST: 3.902
mean: 2.229
median: 1.933
low: 0.756
 Quick Ratio 3.604
Quick Ratio QoQ -14.905 %
Quick Ratio YoY -20.248 %
Quick Ratio IPRWA high: 11.708
TWST: 3.604
mean: 1.72
median: 1.496
low: 0.701
COVERAGE & LEVERAGE
 Debt To EBITDA -3.249
 Cost Of Debt 0.179 %
 Interest Coverage Ratio -210.629
Interest Coverage Ratio QoQ -22.789 %
Interest Coverage Ratio YoY -99.753 %
Interest Coverage Ratio IPRWA high: 33.857
mean: 7.21
median: 5.23
low: -23.105
TWST: -210.629
 Operating Cash Flow Ratio 0.292
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 19.559
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 8.057 %
 Revenue Growth 3.518 %
Revenue Growth QoQ -23.505 %
Revenue Growth YoY -57.008 %
Revenue Growth IPRWA high: 27.38 %
mean: 4.987 %
median: 4.728 %
TWST: 3.518 %
low: -18.123 %
 Earnings Growth -28.788 %
Earnings Growth QoQ -217.368 %
Earnings Growth YoY -133.445 %
Earnings Growth IPRWA high: 71.304 %
mean: 6.188 %
median: 4.078 %
TWST: -28.788 %
low: -61.905 %
MARGINS
 Gross Margin 53.403 %
Gross Margin QoQ 7.661 %
Gross Margin YoY 23.344 %
Gross Margin IPRWA high: 89.231 %
TWST: 53.403 %
mean: 46.468 %
median: 40.612 %
low: 3.787 %
 EBIT Margin -31.356 %
EBIT Margin QoQ -25.414 %
EBIT Margin YoY -70.082 %
EBIT Margin IPRWA high: 65.47 %
median: 19.467 %
mean: 19.345 %
TWST: -31.356 %
low: -167.282 %
 Return On Sales (ROS) -31.356 %
Return On Sales QoQ -25.414 %
Return On Sales YoY -70.082 %
Return On Sales IPRWA high: 40.537 %
median: 17.652 %
mean: 17.174 %
TWST: -31.356 %
low: -167.282 %
CASH FLOW
 Free Cash Flow (FCF) -10.56 M
 Free Cash Flow Yield -0.555 %
Free Cash Flow Yield QoQ -20.601 %
Free Cash Flow Yield YoY 116.797 %
Free Cash Flow Yield IPRWA high: 13.177 %
median: 0.637 %
mean: 0.599 %
TWST: -0.555 %
low: -16.613 %
 Free Cash Growth -38.325 %
Free Cash Growth QoQ 38.312 %
Free Cash Growth YoY -39.487 %
Free Cash Growth IPRWA high: 206.094 %
median: 206.094 %
mean: 120.89 %
TWST: -38.325 %
low: -222.423 %
 Free Cash To Net Income -0.518
 Cash Flow Margin 26.436 %
 Cash Flow To Earnings 1.245
VALUE & RETURNS
 Economic Value Added 0.04
 Return On Assets (ROA) 3.291 %
Return On Assets QoQ -150.383 %
Return On Assets YoY -125.785 %
Return On Assets IPRWA high: 3.831 %
TWST: 3.291 %
mean: 1.711 %
median: 1.615 %
low: -14.729 %
 Return On Capital Employed (ROCE) -5.412 %
 Return On Equity (ROE) 0.043
Return On Equity QoQ -147.717 %
Return On Equity YoY -124.473 %
Return On Equity IPRWA high: 0.104
TWST: 0.043
mean: 0.035
median: 0.032
low: -0.217
 DuPont ROE 4.441 %
 Return On Invested Capital (ROIC) -6.24 %
Return On Invested Capital QoQ 17.337 %
Return On Invested Capital YoY -124.082 %
Return On Invested Capital IPRWA high: 5.983 %
mean: 2.475 %
median: 2.332 %
TWST: -6.24 %
low: -17.594 %

Six-Week Outlook

Near-term price action should remain choppy as technicals and fundamentals pull in different directions. Bullish momentum indicators (MACD crossing above its signal and a negative MRO suggesting mean-reversion) support the possibility of a rally toward near-term resistances around the $28.00–$29.00 range, but bearish directional signals (DI+ peak, DI- dip, price below the 50- and 200-day averages) raise the probability of failed breakouts and renewed pressure if volume fails to expand.

Fundamentals temper the outlook: ample cash and conservative leverage reduce tail-risk while operating losses and weak QoQ/YoY revenue trends limit conviction for a sustained trend shift. Expect range-bound trading with higher sensitivity to company updates, institutional activity, and any confirmation of improving operating margins or cash-flow generation. Monitor momentum confirmation before extrapolating sustained upside from the current technical setup.

About Twist Bioscience Corporation

Twist Bioscience Corporation (NASDAQ:TWST) develops and markets synthetic DNA-based products for a wide range of applications. The company manufactures synthetic genes and gene fragments utilized in the development of therapeutics, diagnostics, chemicals, materials, food, agriculture, and data storage. Twist Bioscience serves biotech, pharmaceutical, industrial chemical, and agricultural sectors, as well as academic research institutions. Their product offerings include oligo pools for targeted next-generation sequencing (NGS), CRISPR gene editing, and DNA computing, among other uses. The company also provides immunoglobulin G proteins for drug discovery and development. Twist Bioscience’s NGS tools encompass library preparation kits, human exome kits, and custom panels, aiding in diagnostic tests, population genetics, biomarker discovery, and more. Additionally, they offer methylation detection kits for cancer and rare disease research, synthetic RNA reference sequences for SARS-CoV-2, and controls for various respiratory viruses. Their precision DNA libraries support antibody engineering, and their antibody optimization solutions enhance multiple antibody characteristics. Established in 2013, Twist Bioscience operates from its headquarters in South San Francisco, California.



© 2025 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.